Yttriga radiopharmaceutical precursor, solution

Do not use Yttriga:

- if you are allergic (hypersensitive) to Yttrium ( 90Y) chloride or any of the other ingredients of Yttriga.

• if you are pregnant or if there is a possibility that you may be pregnant (see below).

Take special care with Yttriga

• Yttriga is a radioactive medicine and is only used in combination with another medicinal product. It is not intended for direct use in patients.
• Because there are strict laws covering the use, handling and disposal of radiopharmaceuticals, Yttriga will always be used in a hospital or a similar setting. It will only be handled and administered by people who are trained and qualified in the safe handling of radioactive material.

Particular care should be taken when administering radioactive medicinal products to children and adolescents (from 2 to 16 years old).

Taking other medicines

Please tell your doctor or pharmacist, if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.
No interaction of Yttrium ( 90Y) chloride with other medicines are known as no clinical studies are available.

Pregnancy and breast-feeding

Women of childbearing potential should use effective contraception during and after treatment. Please tell your doctor if there is any possibility that you are pregnant. If you have missed a period, you should assume to be pregnant until a pregnancy test conducted is negative.

Yttriga is contraindicated in Pregnancy.
Your doctor will consider alternative techniques which do not involve ionising radiation.

Your doctor will ask you to stop breast-feeding.

Ask your doctor or pharmacist for advice before taking any medicine.

Your doctor will not administer Yttriga directly.

Dose

Your physician will decide on the amount of Yttriga, which you will receive for the treatment.

Method of administration

Yttriga is intended for radiolabelling of medicinal products to treat specific diseases, which are subsequently administered by approved route.

If Yttriga is administered inadvertently

Yttriga is administered after being combined with another medicine by your doctor under strictly controlled conditions. The risk to receive a possible overdose is small. However, should this occur, you will receive appropriate treatment from your doctor.

Like all medicines, Yttriga can cause side effects, although not everybody gets them.

For more information, refer to the package leaflet of the particular medicinal product to be radiolabelled.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Keep out of the reach and sight of children.

Do not use Yttriga after the expiry date and time which is stated on the label after EXP.

Store in accordance with local regulations for radioactive substances.

Any unused product or waste material should be disposed of in accordance with local requirements.

What Yttriga contains

- - The active substance is Yttrium 90Y chloride. 1 ml sterile solution contains 0.1-300 GBq Yttrium 90Y on the reference date and time corresponding to 0.005-15 micrograms of Yttrium 90Y as Yttrium 90Y chloride. The other ingredient is hydrochloric acid 0.04 M.

What Yttriga looks like and contents of the pack

Colourless type I glass vial of 3 ml with a V-shapped bottom or a 10 ml with a flat bottom with a PTFE faced chlorobytylrubber stopper or silicon stopper, closed with an aluminium seal.

Radiopharmaceutical precursor, solution.
Colourless clears sterile solution.

Marketing Authorisation Holder and Manufacturer

Eckert & Ziegler Nuclitec GmbH
Gieselweg 1,
D-38110 Braunschweig
Germany
Tel +49- 05307-932262
Fax +49- 05307-932337
e-mail

This leaflet was last approved in